A new company will develop “next-generation mRNA” projects, amid another mRNA setback.
ApexOnco Front Page
Recent articles
Persevera is a bust, but Roche hasn’t given up on the front line.
The company will license EGFR and cMet inhibitors from Celyn.
The company's partner MediLink will start a pivotal trial of beruzatatug pelitecan in lung cancer.
TARA-002 goes from looking better than Inlexzo to seeming rather worse.
After several discontinuations, a new ADC enters the clinic.
Hutchmed goes pivotal with HMPL-760 in B-cell lymphoma.
Median PFS appears to back earlier response rate promise.
